2022.03.15
SHANGHAI and GAITHERSBURG, Md. , March 15, 2022 /PRNewswire/ -- I-Mab ( " I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provides updates on the recent development
2022.01.14
The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects SHANGHAI and   GAITHERSBURG, MD ., Jan. 14, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage
2022.01.06
SHANGHAI and  GAITHERSBURG, MD., Jan. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the senior management team of the Company,
Displaying 11 - 19 of 19